The Eli Lilly-backed liver disease drug developer floated at the top of its range to raise almost $128m, following $207m of venture funding.
Terns Pharmaceuticals, a US-based liver disease therapeutics developer that counts pharmaceutical firm Eli Lilly as its largest investor, has secured approximately $128m in its initial public offering. The offering consisted of 7.5 million shares issued on the Nasdaq Global Market priced at the top of its $15 to $17 range. The company floated on Friday…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.